Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...

Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...

Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against the ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

Rising air pollution, changes in hormone levels, immune system imbalances and longer life expectancy are increasing the risk ...

The study reveals SGLT-2is are linked to fewer COPD exacerbations in type 2 diabetes, suggesting a need for further clinical ...

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

The Department of Trade and Industry-Bureau of Marketing and Development Promotions Office (DTI-BMDPO), in collaboration with key government agencies, proudly presents the first-ever ...